Sjögren’s Disease (SjD) Epidemiology Forecast 2026-2035

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Region

Japan

High-Risk Population

Women, particularly those in middle and older age groups, constitute the principal diagnosed population. Patients with other autoimmune connective-tissue diseases, including rheumatoid arthritis and systemic lupus erythematosus, are also at increased risk of SjD. Individuals with anti-Ro/SSA antibodies and systemic autoimmune activity represent an important clinically enriched population.

Key Diagnostic Method

Diagnosis relies on a combination of sicca symptoms, objective ocular and oral testing, anti-Ro/SSA antibody assessment, and, when appropriate, minor salivary-gland biopsy. The 2016 ACR/EULAR classification framework gives particular diagnostic weight to anti-Ro/SSA positivity and salivary-gland histopathology, supported by objective measures of glandular dysfunction.

Major Risk Factor

Female sex and autoimmune susceptibility are the principal epidemiological associations. Genetic predisposition, immune dysregulation, coexisting autoimmune disease, and environmental or infectious triggers may contribute. Chronic hepatitis C is associated with SjD, although infection-associated sicca must be distinguished from primary autoimmune SjD during diagnosis.

Major gap in the market

Major gaps include delayed diagnosis, heterogeneous application of classification criteria, limited objective testing outside specialist centers, inadequate systematic assessment of extraglandular disease, and limited disease-modifying treatment options for systemic SjD. Diagnostic uncertainty is particularly important because clinically diagnosed prevalence substantially exceeds clinically confirmed prevalence in some contemporary datasets.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

A 2024 umbrella review estimated Sjögren’s prevalence at approximately 60-70 per 100,000 and annual incidence at 6.92 per 100,000, while emphasizing variation among systematic reviews. A 2024 French national claims study identified 23,848 patients with primary SjD and 14,809 with SjD associated with another autoimmune disease in its national database analysis. A U.S. commercial-insurance analysis reported diagnosed SjD prevalence increasing from 195.95 per 100,000 in 2019 to 259.20 per 100,000 in 2023.

Gender-Specific Cases of the Disease

SjD has a pronounced female predominance. The 2024 French national claims study reported women representing approximately 90-91% of primary SjD and 92–93% of SjD associated with another autoimmune disease. A 2026 German review estimates that women are affected approximately ten times more often than men. The magnitude of female predominance varies somewhat according to whether primary, secondary, or clinically confirmed disease is evaluated.

Age-Specific Cases of the Disease

SjD may develop at any age but is predominantly diagnosed during middle and later adulthood. The 2023 systematic literature review found the highest incidence in individuals aged ≥65 years and the highest prevalence in those aged ≥75 years. Contemporary clinical reviews generally describe symptom onset and diagnosis as concentrated around the fifth to seventh decades, although pediatric and young-adult disease occurs and may be under-recognized.

Ethnicity-Wise Cases of the Disease

Reliable ethnicity-specific population estimates remain limited. The epidemiological literature shows substantial geographic and methodological heterogeneity, preventing robust global comparisons. Contemporary U.S. data from Alaska Native and American Indian populations reported age-adjusted SjD prevalence of 199 per 100,000 adults, including 129 per 100,000 for primary SjD and 70 per 100,000 for secondary SjD, demonstrating that substantial disease occurs in Indigenous populations.

Mortality and Survival Analysis of the Disease

SjD is associated with a modest but measurable increase in mortality at the population level. A 2024 umbrella review reported pooled standardized mortality ratios of approximately 1.38-1.48. A 2025 prospective SjD cohort of 314 patients followed for a median of 9.5 years reported a standardized mortality ratio of 1.7, corresponding to approximately 70% higher mortality than expected in the matched general population. Systemic organ disease and lymphoproliferative complications contribute to adverse outcomes.

Disease Type

Prevalence

Primary Sjögren’s Disease

Primary Sjögren’s Disease occurs independently of another established systemic autoimmune connective-tissue disease and represents the principal epidemiological phenotype studied in contemporary literature. Reported prevalence varies substantially according to diagnostic criteria, ranging from approximately 60-70 per 100,000 in recent umbrella-review estimates to higher values in claims-based datasets. The phenotype includes both glandular symptoms and variable systemic manifestations.

Secondary or Associated Sjögren’s Disease

SjD may occur alongside another systemic autoimmune disease, particularly rheumatoid arthritis or systemic lupus erythematosus. Contemporary French national claims data separately identified 14,809 patients with SjD associated with another autoimmune disorder, compared with 23,848 patients classified as primary SjD. Associated disease therefore represents a clinically important population, although prevalence depends strongly on the definition and underlying autoimmune cohort.

Country

Key Insights

United States

Contemporary U.S. commercial-insurance data showed diagnosed SjD prevalence increasing from 195.95 per 100,000 in 2019 to 259.20 per 100,000 in 2023. Prevalence was higher among women and concentrated in the 45-64 and ≥65-year age groups. A separate 2025 study of Alaska Native and American Indian adults reported age-adjusted SjD prevalence of 199 per 100,000, including 129 per 100,000 for primary SjD.

Germany

A 2026 German review estimates SjD prevalence at approximately 7 per 10,000 population, or about 70 per 100,000, with women affected approximately ten times more often than men. Earlier German systematic evidence reported a substantially wider 0.07-0.77% range for SjD/sicca syndrome because of heterogeneous routine-data definitions. Contemporary German authors emphasize the need for improved objective classification and epidemiological surveillance.

France

A national French claims analysis published in 2024 identified 23,848 primary SjD and 14,809 SjD-associated autoimmune disease cases. During the analyzed national period, estimated primary SjD prevalence ranged from 23 to 32 per 100,000 and associated SjD from 16 to 20 per 100,000, with women accounting for approximately 90-93% of identified cases. The investigators noted substantial clinical and economic burden.

Italy

No contemporary nationwide population-based SjD prevalence estimate with sufficiently standardized case ascertainment was identified in the 2023-2026 literature reviewed. Italian centers contribute substantially to European SjD cohorts and systemic-disease research, but available studies are predominantly specialist or regional cohorts. Consequently, national Italian prevalence should not be inferred from individual rheumatology-center series.

Spain

Contemporary nationwide SjD surveillance remains limited. A population-based Spanish study reported primary SjD prevalence of 0.25% in adults, but that study predates the requested 2023-2026 evidence window and is therefore not used as a current estimate here. Recent epidemiological reviews continue to identify substantial heterogeneity between Spanish and other European estimates, largely related to classification and ascertainment methods.

United Kingdom

A large UK population-based cohort study of 22 million individuals, published in 2023, found that Sjögren’s syndrome was among the autoimmune diseases showing the largest increases in incidence over the study period, with an incidence rate ratio of 2.09 (95% CI: 1.84–2.37). More recent English population-level research published in 2025 found that SjD incidence remained relatively stable during 2012–2023, while SjD had the lowest age-standardized mortality rate among the connective-tissue diseases evaluated.

Japan

Recent Japanese evidence has strengthened the available epidemiological picture. A nationwide study using Japan’s National Database of Designated Intractable Diseases analyzed 7,444 patients with primary SjD and clinically significant systemic disease activity, demonstrating a substantial contemporary patient population and marked heterogeneity in disease severity. In addition, the 2024 systematic literature review confirms considerable variability in reported Sjögren’s epidemiology across countries and diagnostic definitions.

India

Contemporary national prevalence data remain insufficient. Indian studies continue to document clinically important systemic SjD, including renal disease. A recent North Indian multicenter study of patients with renal involvement reported 38 cases, 94.7% female, with mean age 41.4 years; 63% had eGFR below 60 mL/min/1.73 m². These findings demonstrate substantial organ morbidity but cannot be extrapolated to national SjD prevalence.